Please ensure Javascript is enabled for purposes of website accessibility

FDA Approves First Drug for Peanut Allergy

By Jim Crumly - Feb 3, 2020 at 6:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The first approved drug for any food allergy may be the first of several from Aimmune Therapeutics.

The U.S. Food and Drug Administration (FDA) approved the first treatment for peanut allergies late Friday, and shares of the company that developed it, Aimmune Therapeutics (AIMT) rose 6.4% today on the news. Palforzia is the first FDA-approved therapy for any food allergy and becomes Aimmune's first commercial product.

Palforzia is an immunotherapy designed to desensitize patients to potentially life-threatening allergic reactions to peanuts and is approved for use with patients aged 4 through 17. Children with a severe peanut allergy are at risk of accidental exposure to trace amounts of peanuts in the environment or in foods that may not even have peanuts as a listed ingredient, potentially resulting in anaphylaxis.

Boy holding up hand to bowl of peanuts.

Image source: Getty Images.

The treatment, a complex biologic drug that's derived from peanuts themselves, won't allow patients to eat peanuts freely but results from a clinical trial last year showed that 58% of patients treated with Palforzia tolerated peanut protein equivalent to three or four peanuts, compared with 2.3% in the placebo group. Aimmune has priced the drug at $890 per month, with a co-pay program to help bring down the out-of-pocket cost.

Aimmune says the milestone is just the beginning. The specialist in food allergies is awaiting approval for Palforzia in Europe and is conducting a trial for the drug in children between 1 and 4 years old. It also has products in its pipeline for egg and tree nut allergies.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aimmune Therapeutics, Inc. Stock Quote
Aimmune Therapeutics, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.